Decision Support in Texas

Ansh Labs, a VION Biosciences company based in Webster, Texas, is a specialized biotechnology firm founded in 2010 that develops, manufactures, and distributes high-quality immunodiagnostic assays, reagents, and ELISA kits for biomedical research and clinical diagnostics. The company leverages in-house antibody development and characterization capabilities to create immunoassays targeting clinically significant biomarkers. Ansh Labs offers validated ELISA immunoassays with rapid turnaround times, high specificity, and excellent sensitivity—supporting 24-month shelf lives and straightforward procedures. Core service offerings include contract development of custom immunoassays, immunoassay method development and validation, assay optimization, cross-reactivity testing, and preclinical biomarker testing. The company serves life science researchers, hospitals, commercial laboratories, and public health agencies, with particular expertise in areas such as cancer diagnostics, fertility biomarker testing, obesity research, and specialty assays for glucagon regulation and reproductive health. Following its acquisition by VION Biosciences in August 2024, Ansh Labs continues to maintain its team and product portfolio while expanding its service capabilities.

AirStrip Technologies develops clinical surveillance and alarm management software that consolidates siloed clinical data from EMRs, bedside monitors, and medical devices into vendor-agnostic mobile and web applications. The platform provides real-time patient monitoring with embedded waveforms, automated protocol management, and visual decision support across ICU, Emergency, Obstetrics, Cardiology, and Rapid Response units. Core capabilities include multi-patient monitoring (up to 40 patients per screen), diagnostic-quality 12-lead ECG capture with STEMI notifications, maternal and fetal waveform monitoring with real-time visualization, and comprehensive alarm triage and analytics. The software features digitized peer-reviewed clinical protocols, alarm trend analysis and responsiveness metrics, and context-aware clinical linking. AirStrip integrates with diverse hospital infrastructure systems while maintaining HIPAA compliance and meeting ISO 27001 security standards. The platform supports telemetry optimization workflows, door-to-balloon time reduction for acute coronary syndromes, and multi-unit alarm management at scale. Named one of TIME's World's Top HealthTech Companies in 2025 with an "outstanding" rating.

MEDITECH (Medical Information Technology, Inc.) is a leading electronic health record (EHR) and health information technology vendor serving health systems, hospitals, and clinics of all sizes globally. The company develops and delivers MEDITECH Expanse, an intelligent EHR platform incorporating predictive analytics, genomics integration, and AI-infused clinical decision support. MEDITECH Expanse is designed to improve physician workflow, increase clinical and operational efficiency, enhance sustainability, and support data-driven care delivery across inpatient and outpatient settings. The platform emphasizes interoperability through solutions like Traverse Exchange, enabling secure data access from both internal and external sources. MEDITECH serves diverse market segments including large integrated delivery networks (190+ hospitals across 20 U.S. states and international locations), independent community health systems, specialty facilities (brain injury rehabilitation, precision medicine centers), and rural hospitals. The company's customer base includes prominent organizations such as HCA Healthcare, UPMC Ireland, Humber River Health, Willis Knighton Health, and Frederick Health. MEDITECH has earned 12 consecutive KLAS Research "Best in KLAS" awards and recognition from CHIME Digital Health Most Wired. The EHR platform includes patient engagement features (Expanse Patient Connect with automated secure texting), interoperability capabilities, and customizable configurations to support facility-specific workflows. MEDITECH emphasizes partnership, stability, and long-term support for healthcare organizations seeking to remain independent while adopting state-of-the-art digital health infrastructure.

BrainCheck is a software platform for cognitive assessment and care planning, headquartered in Austin, Texas with operations in New York City. The company develops FDA-registered Class II digital cognitive assessment tools designed to integrate into clinical workflows for neurologists, psychiatrists, primary care providers, and clinical researchers. BrainCheck Assess, the platform's flagship product, is a 15-minute cognitive evaluation spanning five domains that detects subtle signs of cognitive impairment, potentially associated with dementias including Alzheimer's disease. The platform comprises 30+ clinical evaluation tools including validated screeners, assessments, and surveys. Published peer-reviewed research demonstrates that BrainCheck Assess scores correlate highly with the Montreal Cognitive Assessment (MoCA, r=0.77) and can distinguish between normal cognition, mild cognitive impairment, and dementia with high sensitivity and specificity. The platform supports seamless integration with major electronic health record systems (Epic, athenahealth) to enable cognitive screening, assessment, interpretation, care planning, and follow-up within routine care. BrainCheck's clinical validation is supported by a normative database of 5,000+ patients and real-world data from 450,000+ patient assessments. The company collaborates with leading academic and research institutions including University of Texas at Austin, Johns Hopkins University, Mount Sinai, Stanford University, and MD Anderson Cancer Center. U.S.-based clinical and technical support is available for product use, documentation, and billing inquiries.

Varian Medical Systems, a Siemens Healthineers company, specializes in cancer care solutions across the entire patient journey, including radiation oncology, adaptive therapy, interventional oncology, and image-guided treatment systems. Primary product lines include TrueBeam and Edge external beam radiotherapy systems with integrated image-guided capabilities, Ethos Therapy (an AI-powered adaptive intelligence platform for personalized cancer delivery), Halcyon platform for streamlined radiotherapy, RapidArc dynamic treatment planning, HyperSight imaging solution for enhanced real-time visualization, and IntelliBlate microwave ablation for interventional oncology. The company develops treatment planning software, dose calculation engines, and connected workflows for cancer centers. Products are FDA 510(k) cleared and serve hospital radiation oncology departments, cancer centers, and specialty clinics. Varian provides training, webinars, clinical education, and ongoing customer support. The organization conducts research in radiotherapy innovation and maintains partnerships with clinical institutions globally.

M&S Biotics is an IoT-based healthcare technology company specializing in operating room automation and surgical data analytics. The company develops real-time detection, tracking, counting, and localization systems for surgical instruments and items, designed to minimize surgical count time and improve OR efficiency. M&S Biotics offers three primary solutions: (1) OR Solution—an IoT system that automates surgical counts and provides instrument utilization data to optimize surgical sets; (2) SPD Solution—an IoT-enabled sterilization and processing department system that ensures surgical set accuracy, tracks instrument recovery, reduces shrinkage, and monitors sterilization cycles; and (3) Intraoperative Intervention®—a clinical decision support platform that captures and displays real-time intraoperative analytics through a user-friendly interface. The technology is designed to enhance surgical procedure efficiency, efficacy, and safety by providing autonomous, real-time operational intelligence previously unavailable in the OR. M&S Biotics partners with major healthcare organizations and device manufacturers, including Johnson & Johnson. The company is headquartered in Houston, Texas, at the Center for Device Innovation within the Texas Medical Center.

Seno Medical Instruments develops the Imagio® Breast Imaging System, an opto-acoustic (photoacoustic) imaging platform for breast cancer diagnostics. The system combines light and sound technology to deliver real-time, functional diagnostic imaging that assesses breast masses for benign versus malignant characteristics in a single exam, without ionizing radiation. The company's flagship product is enhanced by SenoGram®, a proprietary AI-driven clinical decision support application designed to improve diagnostic accuracy and reduce false-positive biopsies. Imagio® addresses significant gaps in current breast imaging workflows by reducing diagnostic delays (median 34 days to diagnosis in standard pathways), minimizing unnecessary biopsies (50.4% false-positive rate in traditional screening), and improving patient experience. The system targets radiologists, imaging centers, and healthcare systems seeking to increase diagnostic confidence, streamline workflows, and reduce overall costs associated with inconclusive findings and repeat procedures. Seno Medical delivers training through its Seno University program to facilitate clinical integration. The technology leverages opto-acoustic principles—combining ultrasound and optical imaging—to visualize tissue morphology and functional properties. Clinical evidence supports the platform's ability to down-classify BI-RADS categories and reduce unnecessary interventions while maintaining cancer detection sensitivity.

Aspira Women's Health is a diagnostic company specializing in AI-powered testing solutions for gynecologic care, with a focus on ovarian cancer risk stratification. The company develops and commercializes non-invasive biomarker-based tests for evaluating adnexal masses and personalizing ovarian cancer risk assessment. Their primary product portfolio, OvaSuite, includes OvaWatch (longitudinal monitoring for indeterminate/benign adnexal masses with reported >99% negative predictive value) and Ova1Plus (reflex testing combining biomarkers including CA-125, menopausal status, and ultrasound findings for surgical management decisions). Ova1Plus employs a two-step algorithm: Ova1 is performed first, and if intermediate risk is detected, Overa is automatically performed for increased specificity. Clinical evidence shows Ova1 detected malignancy risk in early-stage and premenopausal/postmenopausal cases where CA-125 was uninformative. The company emphasizes research-driven development with peer-reviewed publications supporting clinical utility. Products are FDA-cleared and positioned for use in conjunction with imaging and clinical assessment, not as standalone screening tools. Aspira targets obstetricians/gynecologists, gynecologic oncologists, primary care physicians, and hospital laboratories managing patients with adnexal masses.

Asuragen is a molecular diagnostics company specializing in genetic carrier screening and precision oncology testing. Founded in 2006 and acquired by Bio-Techne Corporation in 2021, the company develops advanced diagnostic solutions utilizing proprietary chemistries and miRNA-based technologies. Their product portfolio includes genetic testing kits for inherited disorders (Fragile X, CFTR, SMN1/2, HTT), precision oncology solutions for chronic myeloid leukemia (CML) and solid tumor monitoring, custom molecular quality controls, and armored RNA controls. The AmplideX product line encompasses PCR/CE-based assays optimized for clinical laboratories. Asuragen operates a GMP-compliant manufacturing facility and CLIA-certified laboratory, serving clinical diagnostics and research applications across oncology, genetic disorders, and carrier screening markets. The company maintains strategic partnerships and distributes products across North America and EMEA regions.

Neuromersive Inc (operating as Neuro Rehab VR) is an FDA-registered, HIPAA-compliant virtual reality healthcare technology company specializing in AI-powered immersive XR therapy systems for neurological rehabilitation. Founded in 2017 and based in Fort Worth, Texas, the company develops the Smart Therapy™ Complete Solution—an integrated platform combining VR headsets, motion controllers, clinician tablets, and comprehensive software libraries for evidence-based therapy exercises. The system addresses upper and lower extremity rehabilitation, cognitive therapy, pain management, and anxiety relief through engaging 3D immersive applications. The platform includes an AI-powered analytics portal for real-time progress tracking, automated therapy documentation, and patient management. Clinical evidence demonstrates 92% improvement in patient motivation, 85% pain reduction, 50% reduction in documentation time, and 35% increase in billing ROI. Trusted by major healthcare systems including Cedars-Sinai, MD Anderson, Kaiser Permanente, Penn Medicine, Ascension, and the U.S. Veterans Affairs, Neuro Rehab VR has delivered therapy to over 350 patients across thousands of sessions. The solution serves hospitals, outpatient clinics, skilled nursing facilities, and government healthcare providers.